Advertisement
U.S. markets closed

Geron Corporation (GERN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.3000-0.0100 (-0.30%)
At close: 04:00PM EDT
3.3292 +0.03 (+0.88%)
After hours: 06:18PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Hammer

Hammer

Previous Close3.3100
Open3.3200
Bid3.2700 x 23100
Ask3.3300 x 2700
Day's Range3.2700 - 3.3400
52 Week Range1.6400 - 3.7400
Volume6,212,185
Avg. Volume11,330,568
Market Cap1.941B
Beta (5Y Monthly)0.55
PE Ratio (TTM)N/A
EPS (TTM)-0.3200
Earnings DateMay 09, 2024 - May 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.08
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for GERN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Geron Corporation
    DVAX: What does Argus have to say about DVAX?DYNAVAX TECHNOLOGIES CORP has an Investment Rating of SELL; a target price of $10.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • Zacks

    Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More

    Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates.

  • Business Wire

    Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

    FOSTER CITY, Calif., March 19, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an underwritten offering consisting of 41,999,998 shares of its common stock at a price of $3.00 per share and pre-funded warrants to purchase 8,002,668 shares of its common stock. The pre-funded warrants are being sold at a price of $2.999 per pre-funded warrant. All of the securities in the offering are to be sold by Geron. The offering included

  • Yahoo Finance Video

    Geron, Madrigal Pharmaceuticals jump on good news from FDA

    Shares of both Geron (GERN) and Madrigal Pharmaceuticals (MDGL) are soaring after receiving positive news from the Food and Drug Administration. For Geron, an FDA advisory panel backed its blood disorder treatment. For Madrigal, the FDA approved its treatment for a liver disease known as nonalcoholic steatohepatitis, or NASH. Yahoo Finance's Josh Lipton and Julie Hyman discuss the stocks' reaction in the video above. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Stephanie Mikulich.